Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Inv. presentation
Director departure
Appointed director
IOVANCE BIOTHERAPEUTICS, INC. (IOVA) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/18/2023 8-K Quarterly results
08/08/2023 8-K Quarterly results
Docs: "Iovance Biotherapeutics Reports Second Quarter and First Half 2023 Financial Results and Corporate Updates"
07/13/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Iovance Biotherapeutics Announces Closing of $172.5 Million Common Stock Public Offering"
07/11/2023 8-K Quarterly results
07/10/2023 8-K Results of Operations and Financial Condition, Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "ARTICLE I"
07/10/2023 8-K Quarterly results
06/16/2023 8-K Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Financial Statements and Exhibits...
Docs: "OPEN MARKET SALE AGREEMENT SM June 16, 2023",
"Re: Iovance Biotherapeutics, Inc. Registration Statement on Form S-3ASR"
06/06/2023 8-K Submission of Matters to a Vote of Security Holders  Interactive Data
06/02/2023 8-K/A Financial Statements and Exhibits  Interactive Data
Docs: "CONSENT OF INDEPENDENT AUDITORS",
"Index to Combined Carve-out Financial Statements Report of Independent Auditors ...................................................................................................... 2 Combined Statement of Profit or Loss and Other Comprehensive Income..................................... 4 Combined Statement of Financial Position...................................................................................... 5 Combined Statement of Changes in Parent Company Net Investment ........................................... 6 Combined Statement of Cash flows ................................................................................................ 7 Notes to the Combined carve-out financial statements…………………………&#x202...",
"2 Index to Unaudited Interim Condensed Combined Carve-out Financial Statements Unaudited Interim Condensed Combined Statement of Profit or Loss and Other Comprehensive Income 3 Unaudited Interim Condensed Combined Statement of Financial Position ....................................... 4 Unaudited Interim Condensed Combined Statement of Changes in Parent Company Net Investment 5 Unaudited Interim Condensed Combined Statement of Cash flows .................................................. 6",
"UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL STATEMENTS"
05/18/2023 8-K Completion of Acquisition or Disposition of Assets, Financial Statements and Exhibits  Interactive Data
05/09/2023 8-K Quarterly results
Docs: "Iovance Biotherapeutics Reports First Quarter 2023 Financial Results and Corporate Updates"
04/24/2023 8-K Quarterly results
02/28/2023 8-K Quarterly results
Docs: "Iovance Biotherapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Corporate Updates"
01/27/2023 8-K/A Financial Statements and Exhibits  Interactive Data
Docs: "CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT HAVE BEEN OMITTED AND REPLACED WITH “[***]”. SUCH IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS NOT MATERIAL AND the registrant customarily and actually treats that information as private or confidential. Dated January 2023"
01/23/2023 8-K Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Iovance Biotherapeutics Provides Corporate, Clinical, and Regulatory Updates"
01/10/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "2 © 2023, Iovance Biotherapeutics, Inc. Forward-Looking StatementsCertain matters discussed in this press release are “forward-looking statements” of Iovance Biotherapeutics, Inc. within the meaning of the Private Securities Litigation Reform Act of 1995 . All such written or oral statementsmade in this press release, other than statements of historical fact, are forward-looking statements and are intended to be covered by the safe harbor for forward-looking statementsprovided by the PSLRA. Without limiting the foregoing, we may, in some cases, use terms such as “predicts,” “believes,” “potential,” “continue,” “estimates,” “anticipates,”“expects,” “plans,” &#x2..."
11/18/2022 8-K Quarterly results
11/18/2022 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Iovance Biotherapeutics Provides Update on Biologics License Application Submission for Lifileucel in Advanced Melanoma",
"Iovance Biotherapeutics Announces Updated Clinical Data for Lifileucel in Advanced Melanoma at Society for Immunotherapy of Cancer Annual Meeting",
"Slide Presentation of Iovance Biotherapeutics, Inc"
11/03/2022 8-K Quarterly results
09/12/2022 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Notice of Pendency of Settlement of Action"
08/29/2022 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Iovance Biotherapeutics Initiates Biologics License Application Submission for Lifileucel in Advanced Melanoma",
"TIL 3 1 BTD 1 RMAT"
08/04/2022 8-K Quarterly results
06/13/2022 8-K Quarterly results
05/26/2022 8-K Quarterly results
05/13/2022 8-K Quarterly results
05/05/2022 8-K Quarterly results
04/29/2022 8-K Quarterly results
04/05/2022 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Iovance Biotherapeutics Announces Regulatory and Clinical Updates for Lifileucel in Melanoma"
02/24/2022 8-K Quarterly results
01/19/2022 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
01/10/2022 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Iovance Biotherapeutics Announces Raj K. Puri, M.D., Ph.D. to Join Leadership Team"
11/04/2021 8-K Quarterly results
Docs: "Iovance Biotherapeutics Reports Third Quarter and Year-to-Date 2021 Financial Results and Corporate Updates"
09/23/2021 8-K Quarterly results
08/05/2021 8-K Quarterly results
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy